Remedy's Q2 revenue falls 40% as CONTROL Resonant wishlists top 1.5M; Alan Wake 2 reaches 3M sales

What happened and why it matters

Independent Finnish developer Remedy Entertainment reported a sharp drop in revenue for the second quarter of 2026, while signalling strong early demand for its next release. The studio’s Q2 (April–June 2026) revenue fell 40.0% year‑over‑year to €10.2 million, yet wishlists for CONTROL Resonant have already crossed 1.5 million ahead of its September 24 launch. Remedy also reported that Alan Wake 2 has sold 3 million units.

Financial snapshot

• Q2 2026 revenue (April–June): €10.2 million, down 40.0% from €16.9 million year‑over‑year.
• H1 2026 revenue: €23.3 million, down 23.1% from €30.3 million in the first half of the prior year.
• EBITDA remained marginally positive at €0.5 million.
• Cash flow from operations improved to €7.6 million, which Remedy attributes in part to the timing of incoming receipts (the report does not specify further details).

Why the wishlist and sales numbers matter for players

Wishlists passing 1.5 million for CONTROL Resonant are a clear, early indicator of player interest ahead of the September 24 release. For players, that typically means more visibility for the title in storefronts and more active community discussion and coverage during the run‑up to launch.

The fact that Alan Wake 2 has sold 3 million units underlines ongoing engagement with Remedy’s catalog; it’s a concrete sales milestone that helps put the studio’s current performance into context, even as quarterly revenue slipped.

What to watch next

• September 24: CONTROL Resonant launch and immediate post‑launch reception.
• Post‑launch sales and player engagement for CONTROL Resonant, which will show whether wishlist momentum converts into revenue—Remedy’s report does not include projections or platform breakdowns.
• Next financial updates from Remedy for clarity on whether the H1 revenue decline is temporary or part of a broader trend.